Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading
technology services and consulting company, announced that it is
working with Amazon Web Services (AWS) to redefine the future of
lab processes in the life sciences industry.
The life science and pharmaceutical industries have long
struggled with outdated laboratory processes that hinder efficiency
and increase costs. Lab technicians, lab associates, and medical
specialists often find themselves performing tasks outside of their
expertise due to the fragmentation of laboratory operations across
various platforms. This lack of cohesion not only results in
inefficiencies but also extends the time required to bring new
drugs and products to market, subsequently increasing research and
development expenses.
Recognizing these challenges, Wipro began working with AWS to
create the Lab of the Future. This innovative solution addresses
the root issues that have plagued the industry, offering a
comprehensive, cloud-based platform that streamlines laboratory
processes and enhances collaboration among stakeholders.
“Our vision with launching Lab of the Future is to deliver
holistic lab performance powered by generative AI, advanced
analytics, and a consultative business first approach,” said
Philippe Dintrans, Senior Vice President & Global Head of
Domain & Consulting at Wipro Consulting.
Among the key challenges facing the Life Sciences industry today
are decreasing ROI for R&D (R&D returns fell to 1.8% in
2019, down from 10% in 20101), increasing cost of bringing new
drugs to the market, and the significant amount of time spent on
data management, which takes 45% of data scientists’ time,
according to recent surveys.2
By introducing the Lab of the Future, Wipro and AWS aim to
empower the life sciences industry with a modern, efficient, and
collaborative laboratory solution that has the potential to
significantly reduce costs and accelerate the development of
life-saving drugs and products.
“Wipro has enhanced offerings for clients across the life
sciences value chain and our latest Lab innovation with AWS further
illustrates our commitment to helping our clients improve business
outcomes and enable cost efficiency,” said Srini Rajamani,
Senior Vice President & Sector Head – Consumer and Life
Sciences at Wipro.
The Lab of the Future offers a range of modules and solutions
designed to transform laboratory operations. Among them:
- Lab as a Service: This module focuses on creating and
optimizing labs from the ground up. It includes performance
tracking and risk assessment through the Wipro Total Intelligence
user dashboard.
- Safety Notifications: This module can deliver
notifications to lab staff to alert hazardous events such as
chemical spills and fires, providing immediate action plans in
accordance with standard operating procedures (SOPs) and Material
Safety Data Sheets (MSDS).
- Inventory Management: This module tracks and manages lab
equipment stock, calibration cycles, utilization, wear and tear,
and Internet of Things (IoT) updates, ensuring efficient inventory
management.
- Scientific Information Platform: Provides instant access
to scientific reference information with the help of virtual
subject matter experts.
- Biomarker Hub: This module enables personalized medicine
through DNA sequencing and the integration of digital biomarker
data.
- E-Lab Notebook: Automatically records lab notes during
experiments, reducing the burden of manual documentation.
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading
technology services and consulting company focused on building
innovative solutions that address clients’ most complex digital
transformation needs. Leveraging our holistic portfolio of
capabilities in consulting, design, engineering, and operations, we
help clients realize their boldest ambitions and build
future-ready, sustainable businesses. With nearly 245,000 employees
and business partners across 65 countries, we deliver on the
promise of helping our clients, colleagues, and communities thrive
in an ever-changing world. For additional information, visit us at
www.wipro.com.
Forward-Looking Statements
The forward-looking statements contained herein represent
Wipro’s beliefs regarding future events, many of which are by their
nature, inherently uncertain and outside Wipro’s control. Such
statements include, but are not limited to, statements regarding
Wipro’s growth prospects, its future financial operating results,
and its plans, expectations and intentions. Wipro cautions readers
that the forward-looking statements contained herein are subject to
risks and uncertainties that could cause actual results to differ
materially from the results anticipated by such statements. Such
risks and uncertainties include, but are not limited to, risks and
uncertainties regarding fluctuations in our earnings, revenue and
profits, our ability to generate and manage growth, complete
proposed corporate actions, intense competition in IT services, our
ability to maintain our cost advantage, wage increases in India,
our ability to attract and retain highly skilled professionals,
time and cost overruns on fixed-price, fixed-time frame contracts,
client concentration, restrictions on immigration, our ability to
manage our international operations, reduced demand for technology
in our key focus areas, disruptions in telecommunication networks,
our ability to successfully complete and integrate potential
acquisitions, liability for damages on our service contracts, the
success of the companies in which we make strategic investments,
withdrawal of fiscal governmental incentives, political
instability, war, legal restrictions on raising capital or
acquiring companies outside India, unauthorized use of our
intellectual property and general economic conditions affecting our
business and industry.
Additional risks that could affect our future operating results
are more fully described in our filings with the United States
Securities and Exchange Commission, including, but not limited to,
Annual Reports on Form 20-F. These filings are available at
www.sec.gov. We may, from time to time, make additional written and
oral forward-looking statements, including statements contained in
the company’s filings with the Securities and Exchange Commission
and our reports to shareholders. We do not undertake to update any
forward-looking statement that may be made from time to time by us
or on our behalf.
1 Among 12 leading large-cap biopharma companies, R&D
returns fell to 1.8% in 2019—down from 10% in 2010
https://www.us.jll.com/en/views/real-estate-as-reagent-how-the-right-life-sciences-space-can-drive-innovation
2
https://www.datanami.com/2020/07/06/data-prep-still-dominates-data-scientists-time-survey-finds/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231130989584/en/
Media Contact: Laura Barnes Wipro Limited
laura.barnes@wipro.com
Wipro (NYSE:WIT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Wipro (NYSE:WIT)
Gráfica de Acción Histórica
De May 2023 a May 2024